Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation for Management of Drug-Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Women and men are eligible. Women of reproductive age should apply effective contraception.~* Age ranges from 20 years (inclusive) to less than 70 years.~* Patients should have essential hypertension.~* Treatment-resistant hypertension in patients taking a stable drug regimen for at least 4 weeks consisting of 3 or more antihypertensive medications from different classes, including a diuretic.~* Under maximal therapy, office blood pressure should be ≥140/90 mmHg and the 24-h ambulatory blood pressure should be 130 mm Hg systolic or 80 mm Hg diastolic or higher.~* eGFR must be ≥ 60 mL/min/1.73 m2.~* The patients should accept to have adherence checked before randomisation and during supervised follow-up, but both patients and doctors will remain blinded to the results;~* Informed written consent.~Exclusion criteria:~* Suboptimal clinical context, because of recent history or concurrent disease.~* Isolated systolic and diastolic hypertension.~* Body-mass index ≥ 40kg/m2.~* The anatomy of the renal arteries is suboptimal for renal denervation.~* Pregnancy.~* Alcohol or substance abuse or psychiatric illnesses.~* Participation in other study.~* The clinical context is suboptimal for renal denervation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: OTHER): Standard antihypertensive drug treatment
- Intervention group (Type: EXPERIMENTAL): Renal denervation plus standard antihypertensive drug treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).